Search results for "IPR"

showing 10 items of 1515 documents

Attitudes toward Different Formulations of Psychotropic Drugs

2006

Attitudes toward psychotropic drug treatment are likely to be a factor in medication adherence and outcome, but preferences regarding different drug formulations have been rarely assessed. To explore attitudes toward different drug formulations in a cross-sectional study in psychiatric patients and a comparison group of healthcare professionals. Inpatients (n = 59, age 46 ± 14 years, 63% female) and staff members (n = 96, age 40 ± 10 years, 65% female) of a psychiatric department were surveyed using a questionnaire on attitudes toward 18 possible application forms of psychotropic drugs including newer formulations such as fast-dissolving tablets. The questionnaire asked respondents to rate …

PharmacologyDrugOlanzapinemedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectAlternative medicineMedication adherencePharmacyPharmacologyPreferencePsychotropic drugmedicineZiprasidonebusinessmedia_commonmedicine.drugClinical psychologyAmerican Journal of Drug Delivery
researchProduct

Evaluation of alprazolam-induced behavioural effects: differences with chlordiazepoxide after interaction with desipramine and rolipram, a cAMP phosp…

1989

PharmacologyMaleAlprazolamBehavior Animalbusiness.industryPhosphodiesterase InhibitorsDesipraminePhosphodiesteraseCAMP phosphodiesterase inhibitorChlordiazepoxideRats Inbred StrainsPharmacologyPyrrolidinonesChlordiazepoxideRatsAlprazolamDesipramineAnesthesiaMedicineAnimalsDrug InteractionsbusinessRolipramRoliprammedicine.drugPharmacological research
researchProduct

Head-twitch and forepaw-shake responses after single and repeated treatment with rolipram: interaction with noradrenergic and dopaminergic agonists a…

1988

PharmacologyMaleBehavior AnimalChemistryDopamine AgentsRats Inbred StrainsShakePharmacologyAutonomic AgentsPyrrolidinonesRatsRepeated treatmentForelimbmedicineHead (vessel)AnimalsDopamine AntagonistsDrug InteractionsDopaminergic AgonistsHeadRolipramRoliprammedicine.drugPharmacological research communications
researchProduct

Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.

2008

HIV-infected patients have a higher risk of developing cutaneous reactions than the general population, which has a significant impact on patients' current and future care options. The severity of cutaneous adverse reactions varies greatly, and some may be difficult to manage. HIV-infected patients just at the beginning of antiretroviral treatment can frequently show a wide variety of adverse drug effects such as drug rashes, hyperpigmentation, hair loss, hypersensitivity reactions, injection site reaction, urticarial reaction, erythema multiforme, toxic epidermal necrolysis or Stevens-Johnson syndrome. The early detection and treatment of cutaneous adverse drug reactions, plus identificati…

PharmacologyMicrobiology (medical)Enfuvirtidebusiness.industryAnti-HIV AgentsEtravirineIntegrase inhibitorHIV Infectionsmedicine.diseaseRaltegravirSkin Diseaseschemistry.chemical_compoundInfectious DiseaseschemistryInjection site reactionImmunologymedicineHumansPharmacology (medical)Protease inhibitor (pharmacology)businessTipranavirmedicine.drugMaravirocThe Journal of antimicrobial chemotherapy
researchProduct

Therapeutic monitoring of new antipsychotic drugs.

2004

Typical antipsychotic drugs qualify for therapeutic drug monitoring (TDM) primarily for the following reasons: control of compliance and avoidance of extrapyramidal side effects by keeping chronic exposure to minimal effective blood levels. For the atypical antipsychotic clozapine, drug safety is another reason to use TDM. With regard to the new antipsychotics risperidone, olanzapine, quetiapine, amisulpride, ziprasidone, and aripiprazole, which have been introduced in the clinic during the last few years, the rationale to use TDM is a matter of debate. Positron emission tomography (PET), which enables measurement of the occupancy of dopamine D2 receptors, revealed that receptor occupancy c…

PharmacologyOlanzapinemedicine.diagnostic_testDose-Response Relationship Drugmedicine.drug_classbusiness.industryReceptors Dopamine D2medicine.medical_treatmentAtypical antipsychoticPharmacologyTypical antipsychoticStructure-Activity RelationshipTherapeutic drug monitoringmedicineQuetiapineHumansPharmacology (medical)ZiprasidoneAmisulprideDrug MonitoringAntipsychoticbusinessmedicine.drugAntipsychotic AgentsTherapeutic drug monitoring
researchProduct

Low concentration of ziprasidone in human milk: a case report

2009

Although second-generation antipsychotics are established as the first-line treatment for schizophrenia, female patients are often excluded from this efficient treatment for safety reasons in pregnancy or whilst breastfeeding. For this reason, research on this subject mostly relies on case reports, although there is a great need to establish modern guidelines for treatment. Milk-to-plasma (M:P) ratios have been reported for clozapine (2.79–4.32; Winans, 2001), olanzapine (0.10–0.84; Gardiner et al. 2003), risperidone/9-OH risperidone (0.10–0.42/0.24–0.50; Gentile, 2004) and aripiprazole (0.18–0.20; Schlotterbeck et al. 2007). According to one case report, the infant ingests 0.09–0.43% of th…

PharmacologyOlanzapinemedicine.medical_specialtyPediatricsRisperidonebusiness.industryBreastfeedingPsychiatry and Mental healthPsychiatric historymedicinePsychiatric hospitalQuetiapinePharmacology (medical)AripiprazoleZiprasidonebusinessPsychiatrymedicine.drugThe International Journal of Neuropsychopharmacology
researchProduct

Cardiovascular effects induced by rolipram, a selective cAMP phosphodiesterase inhibitor: Interaction with adrenergic and calcium affecting drugs

1990

PharmacologyPhosphodiesterase InhibitorsHemodynamicschemistry.chemical_elementAdrenergicCAMP phosphodiesterase inhibitorCalciumPharmacologyCalcium Channel BlockersPyrrolidinonesCalcium Channel Agonistschemistry3'5'-Cyclic-AMP PhosphodiesterasesmedicineAnimalsRabbitsSympathomimeticsRolipramRoliprammedicine.drugPharmacological Research
researchProduct

Psychotropic drug competition for [3H]imipramine binding further indicates the presence of only one high-affinity drug binding site on human α1-acid …

1983

PharmacologyPsychotropic DrugsChemistryCircular DichroismReceptors Drugmedia_common.quotation_subjectPharmaceutical ScienceOrosomucoidIn Vitro Techniques3h imipramine bindingPharmacologyBinding CompetitiveAntidepressive AgentsCompetition (biology)Receptors NeurotransmitterKineticsPsychotropic drugα1 acid glycoproteinDrug Binding SiteHumansCarrier ProteinsDialysisProtein Bindingmedia_commonJournal of Pharmacy and Pharmacology
researchProduct

Prediction of Aquatic Toxicity of Benzene Derivatives to Tetrahymena pyriformis According to OECD Principles

2016

Background: Many QSAR studies have been developed to predict acute toxicity over several biomarkers like Pimephales promelas, Daphnia magna and Tetrahymena pyriformis. Regardless of the progress made in this field there are still some gaps to be resolved such as the prediction of aquatic toxicity over the protozoan T. pyriformis still lack a QSAR study focused in accomplish the OECD principles. Methods: Atom-based quadratic indices are used to obtain quantitative structure-activity relationship (QSAR) models for the prediction of aquatic toxicity. Our models agree with the principles required by the OECD for QSAR models to regulatory purposes. The database employed consists of 392 substitut…

PharmacologyQuantitative structure–activity relationshipTetrahymena pyriformisAntiprotozoal AgentsQuantitative Structure-Activity Relationship010501 environmental sciencesBiology01 natural sciencesAcute toxicity0104 chemical sciencesAquatic toxicologyToxicology010404 medicinal & biomolecular chemistryParasitic Sensitivity TestsTest setDrug DiscoveryBenzene derivativesLinear regressionTetrahymena pyriformisBenzene DerivativesBiological systemMonte Carlo MethodAlgorithmsBootstrapping (statistics)0105 earth and related environmental sciencesCurrent Pharmaceutical Design
researchProduct

ACE inhibitor potentiation of bradykinin-induced venoconstriction

1997

1. Angiotensin-converting enzyme (ACE) inhibitors exert their cardiovascular effects not only by preventing the formation of angiotensin II (AII), but also by promoting the accumulation of bradykinin in or at the vessel wall. In addition, certain ACE inhibitors have been shown to augment the vasodilator response to bradykinin, presumably by an interaction at the level of the B2 receptor. We have investigated whether this is a specific effect of the ACE inhibitor class of compounds in isolated endothelium-denuded segments of the rabbit jugular vein where bradykinin elicits a constrictor response which is exclusively mediated by activation of the B2 receptor. 2. Moexiprilat and ramiprilat (< …

PharmacologyRamiprilmedicine.medical_specialtybiologyEnalaprilatBradykininAngiotensin-converting enzymeCaptoprilchemistry.chemical_compoundEndocrinologychemistryInternal medicineACE inhibitorcardiovascular systemmedicinebiology.proteinBradykinin receptorRamiprilatmedicine.drugBritish Journal of Pharmacology
researchProduct